Multi-site modified enkephalin and neurotensin (8-13) coupled cycled hybrid peptide, compounding method and application thereof
A technology of neurotensin and its synthesis method, which is applied in the field of cyclized hybrid peptide and its synthesis, can solve the problems of poor anti-neuropathic pain effect and poor resistance to enzymolysis, and achieve enhanced resistance to enzymolysis and enhanced Effects on transport capacity, improved utilization and efficiency
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
specific Embodiment approach 1
[0057] Specific embodiment 1: In this embodiment, the multi-site modified enkephalin and neurotensin (8-13) coupled cyclic hybrid peptides are hybrid peptide 1, hybrid peptide 2, and hybrid peptide 3 or hybrid peptide 4;
[0058] Wherein the amino acid sequence of hybrid peptide 1 is:
[0059] Dmt-Gly-c(Cys-NMePhe-Met-Cys)-Gly-NMeArg-Lys-Pro-Trp-Tle-Leu;
[0060] The amino acid sequence of hybrid peptide 2 is:
[0061] Dmt-Gly-c(Cys-NMePhe-Leu-Cys)-Gly-NMeArg-Lys-Pro-Trp-Tle-Leu;
[0062] The amino acid sequence of hybrid peptide 3 is:
[0063] Dmt-Gly-c(Cys-NMePhe-Met-Cys)-D-Ala-NMeArg-Lys-Pro-Trp-Tle-Leu;
[0064] The amino acid sequence of hybrid peptide 4 is:
[0065] Dmt-Gly-c(Cys-NMePhe-Leu-Cys)-D-Ala-NMeArg-Lys-Pro-Trp-Tle-Leu.
[0066] In this embodiment, the amino acid sequence "Tyr-Gly-Gly-Phe-Met / Leu" of methionine / leucine enkephalin is modified and cyclized to obtain "Dmt-Gly-c(Cys- NMePhe-Met-Cys)" and "Dmt-Gly-c (Cys-NMePhe-Leu-Cys)" amino acid residue seq...
specific Embodiment approach 2
[0068] Specific embodiment two: the synthetic method of the cyclized hybrid peptide of the multi-site modified enkephalin and neurotensin (8-13) coupling of the present embodiment, comprises the following steps:
[0069] 1. Pretreatment of Wang resin protected by "Fmoc": check the air tightness of the solid phase synthesizer, put the Fmoc-Leu-Wang resin with one amino acid residue into the synthesizer, add dichloromethane and stir for 30-40min, After the resin is fully soaked and swollen, filter the solvent under reduced pressure; the mass ratio of the Fmoc-Leu-Wang resin with one amino acid residue to the volume ratio of dichloromethane is 1g: (7-12)mL;
[0070] 2. Remove the "Fmoc" protecting group: wash the swelled resin with DMF for 3 to 5 minutes, dry it, repeat 3 to 5 times, and then add 20% to 25% vol. Piperidine / DMF deprotection solution, stirred for 5-10 minutes, drained, repeated 2-3 times, then added piperidine / DMF deprotection solution with volume percentage concentr...
specific Embodiment approach 3
[0078] Embodiment 3: This embodiment differs from Embodiment 2 in that the molar weight of the amino acid protected by the "Fmoc" group in step 3 is 2.5-3 times the molar weight of the Fmoc-Leu-Wang resin. Others are the same as in the second embodiment.
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com